JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB323457

Anti-SARS-CoV-2 Spike Glycoprotein S1 [EPR24852-116] - Mouse IgG1 (Chimeric) - BSA and Azide free

Be the first to review this product! Submit a review

|

(0 Publication)

Mouse Recombinant Monoclonal SPIKE antibody. Carrier free. Suitable for I-ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples.
1 Images
Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 [EPR24852-116] - Mouse IgG1 (Chimeric) - BSA and Azide free (AB323457)
  • I-ELISA

Lab

Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 [EPR24852-116] - Mouse IgG1 (Chimeric) - BSA and Azide free (AB323457)

Indirect ELISA- Rabbit monoclonal [EPR24852-116] to SARS-CoV-2 Spike Glycoprotein S1 - Mouse IgG1 (Chimeric) (ab323455).

Indirect ELISA showing primary antibody ab323455 binding to Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105). Plates were coated with Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera, ab272105), Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S2 (Fc Chimera, ab272106) and Recombinant human coronavirus SARS spike glycoprotein (Tagged, ab270844) at 1000 ng/ml. Binding of ab323455 was assessed in a serial dilution range 0.016- 1000 ng/mL (a 3-fold serial dilution). Secondary antibody, Goat Anti-Mouse IgG Fc (HRP) preadsorbed (ab98717) was used at 1 : 5000.

This data was developed using the same antibody clone in a different buffer formulation.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

EPR24852-116

Isotype

IgG1

Carrier free

Yes

Reacts with

SARS-CoV-2

Applications

I-ELISA

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

Our data (not shown) suggests this RabMAb is interacting with the non-receptor binding domain of SARS-CoV-2 Spike Glycoprotein S1 with a higher affinity (~ 71x ) than the receptor binding domain of SARS-CoV-2 Spike Glycoprotein S1.
This antibody cross-reacts with the SARS-CoV-2 Omicron variant spike protein.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Recombinant fragment - SARS-CoV-2": { "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "<p></p>" }, "SARS-CoV-2": { "IELISA-species-checked": "predicted", "IELISA-species-dilution-info": "", "IELISA-species-notes": "" } } }

You may be interested in:

AB275299

SARS-CoV-2 IgM ELISA Kit

0

0 Reviews

View product

We recommend this product because it’s often used in the same experiment or related research.

We advise that you always check the datasheet to ensure it fits your experiments, or contact ourtechnical teamfor help.

Product details

This mouse monoclonal chimeric antibody has been engineered from a RabMAb parent antibody (ab283942). By necessity, some rabbit sequence is retained as part of the variable domain. When multiplexing with other rabbit-derived antibodies, using cross absorbed Fc-reactive secondary antibodies are recommended.

ab323457 is the carrier-free version of ab323455

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Constituents: 100% PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Glycoprotein S1 also known as the G10 spike or glycoprotein spike plays an important role in allowing the virus to attach and enter host cells. This protein with a mass of approximately 180 kDa is located on the surface of the virus and forms the outer spikes observed in coronaviruses. Expression of the spike glycoprotein is in virus-infected cells where it facilitates the interaction with host cell receptors. The S1 subunit includes a receptor-binding domain that specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptors initiating the infection process.
Biological function summary

The spike glycoprotein S1 mediates the fusion of the viral and cellular membranes which is necessary for viral entry. It forms part of a larger trimeric complex comprising S1 and S2 subunits. This complex undergoes conformational changes that drive the membrane fusion process. The glycoprotein contains multiple glycosylation sites which help shield the virus from the host immune response. The proper function and presentation of this glycoprotein are critical for efficient viral spread and infection establishment.

Pathways

The spike glycoprotein S1 is integral to the viral infection pathway and host immune evasion. It interacts with the renin-angiotensin system by binding to the ACE2 receptor disrupting normal receptor activity. This interaction not only facilitates viral entry but also impacts the homeostatic functions typically mediated by ACE2 which include blood pressure regulation. Additionally the spike protein is involved in downstream activation of immune signaling pathways including those related to inflammation and cytokine production which may involve proteins such as IL-6.

Infection with the spike glycoprotein S1 is directly related to COVID-19. The binding to ACE2 receptors is linked to the pathology of the disease contributing to respiratory symptoms and in severe cases acute respiratory distress syndrome (ARDS). Through the IL-6 signaling pathway the spike protein is indirectly connected to cytokine release syndrome often observed in severe COVID-19 cases. This connection highlights the importance of targeting this glycoprotein for potential therapeutic interventions and diagnostics such as ELISA SARS-CoV-2 tests and the development of anti-spike antibodies available on platforms like antispark.com for research and clinical purposes.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com